Antibodies News and Research

RSS

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s.

29 Aug 2014

Researchers reveal transmission rate of MERS coronavirus

The MERS coronavirus has caused disease outbreaks across the Arabian Peninsula and spread to Europe several times. The severe pneumonia virus has claimed the lives of several hundred people since its discovery in 2012.

29 Aug 2014

Pixcelldata, eX-Path announce major new deal in advance of ECP 2014

Pixcelldata, the innovative Irish developer of digital pathology management and collaboration software has announced a major new deal with Dutch based eX-Path, global providers of tele-pathology services, founded by renowned pathology expert, Dr. Marius Nap.

29 Aug 2014

CTC clusters cause metastasis

Circulating tumor cell (CTC) clusters - clumps of from 2 to 50 tumor cells that break off a primary tumor and are carried through the bloodstream - appear to be much more likely to cause metastasis than are single CTCs, according to a study from investigators at the Massachusetts General Hospital Cancer Center.

29 Aug 2014

Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola.

29 Aug 2014

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy.

28 Aug 2014

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.

28 Aug 2014

Researchers report possible therapy that could help treat patients infected with SUDV

Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies.

28 Aug 2014

New biomarker may improve diagnosis of early-stage rheumatoid arthritis

A novel biomarker for rheumatoid arthritis (RA) has significant potential to help physicians better identify early-stage disease, when treatment can often arrest further disease progression and disability, according to a new study in The Journal of Rheumatology.

From Quest Diagnostics 28 Aug 2014

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.

28 Aug 2014

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans.

26 Aug 2014

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody.

25 Aug 2014

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform.

25 Aug 2014

Statistical genetic analysis can detect aggressiveness of lymphoma

Each year, more than one thousand Norwegians develop lymphoma. A statistical genetic analysis can detect when the disease will be aggressive. Thereby, treatment can be initiated in time.

25 Aug 2014

SeraCare Life Sciences announces launch of new ACCURUN 501 C. difficile Control

SeraCare Life Sciences, a provider of high-quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of its new ACCURUN 501 C. difficile Control – the company's first molecular control product targeting hospital acquired infections.

23 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

Research offers hope to patient suffering from Duchenne muscular dystrophy

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

21 Aug 2014

OMRF receives $14.5 million grant from NIH to continue research on anthrax

The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a five-year, $14.5 million grant to continue its research on anthrax and the bacteria's effects on humans.

21 Aug 2014

Using a nanotech microchip to diagnose type 1 diabetes: an interview with Dr. Brian Feldman, Stanford School of Medicine

The most common form of diabetes is sometimes referred to as metabolic diabetes, which is the diabetes most people are very familiar with, type 2 diabetes. This form of diabetes is most prevalent in people that are overweight or obese. Historically, it has been confined to adults or older patients but it has been on the rise as the global obesity problem has continued to worsen.

20 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014